Dr. Reddy's Laboratories (DRREDDY) — Financial Results

Dr. Reddy's Laboratories reported Q2 FY26 consolidated revenues of ₹8,805 crores, growing 9.8% YoY with 3% QoQ growth. EBITDA stood at ₹2,351 crores (26.7% margin), while PAT reached ₹1,437 crores (16.3% margin), up 14% YoY. The company acquired Stugeron® brands across 18 markets, launched novel gastro-intestinal drugs in India, and achieved positive EMA opinion for its denosumab biosimilar. Net cash surplus strengthened to ₹2,751 crores. However, regulatory challenges emerged with VAT provision impairments and FDA Form 483 observations at biologics and API facilities.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this financial results affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 24 October 2025?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 24 October 2025

RECLTD REC Limited Financial Results VBL Varun Beverages Limited Financial Results SBICARD SBI Cards and Payment Services Limited Financial Results SBILIFE SBI Life Insurance Company Limited Financial Results SBICARD SBI Cards and Payment Services Limited Financial Results BAJAJ-AUTO Bajaj Auto Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.